Successful treatment of Nocardia actinomycetoma with meropenem and amikacin combination therapy

Abstract

Meropenem and amikacin combination therapy represents an important addition to the currently available treatments for actinomycetomas.

Nocardia harenae, an uncommon causative organism of mycetoma: report on two patients

“…For patients with local or disseminated disease, a three-drug regimen consisting of trimethoprim/sulfamethoxazole, amikacin, and either ceftriaxone or imipenem is preferred because using these drugs in combination prevents drug resistance, eradicates any residual infection and covers all clinical isolates (Brown-Elliott et al, 2006). Remarkably, the chosen treatment of a carbapenem with broad microbicidal activity confirmed our previous observations in that imipenem showed an impressive clinical response (Fuentes et al, 2006;Ameen et al, 2010Ameen et al, , 2011.…”

Newer therapeutic modalities for Actinomycetoma by Nocardia species

“…TMP/SMX was added to linezolid based on its combination in the original Welsh regimen. Penems have been used for cases with bone involvement, but our reason for using an oral penem was primarily because it is a more compliant option than parenteral aminoglycoside.…”

Nocardia and Actinomyces

“…Several successful therapies have been reported with the use of meropenem, alone or in association, in controlling cutaneous [106], pulmonary [107] and even cerebral nocardiosis [108]. The in vitro activity of doripenem is comparable to that of meropenem [104,109].…”